secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2026-02-04T23:59:59+00:00
Accession:  0001193125-26-037558
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Therapeutics appoints Nikhil Aneja as Principal Accounting Officer
-------------------------------------------------------------------------

- Nikhil Aneja appointed Principal Accounting Officer effective January 29, 2026.
- He succeeds Lesley Ann Calhoun, who remains EVP, COO & CFO.
- Aneja has served as VP Finance since Feb 2024; prior roles at CareDx, Blade Therapeutics, Global Blood Therapeutics.
- Aneja, age 49, is a CPA with a Bachelor of Commerce from University of Delhi.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000119312526037558/0001193125-26-037558-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000119312526037558/d12642d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-037558

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer